AUTHORS
Omer Jamy, MD, Kayla Stewart, MS2, Julie Scott, MSN, RN3, Nadia Still, DNP RN4, Debra Wujcik, PhD, RN5
AFFILIATIONS
1 The University of Alabama at Birmingham, Birmingham, Alabama, United States
2 Carevive by Health Catalyst, South Jordan, Utah, United States
3 Carevive by Health Catalyst, South Jordan, Utah, United States
4 Carevive by Health Catalyst, South Jordan, Utah, United States
5 Carevive by Health Catalyst, South Jordan, Utah, United States
ABSTRACT
Introduction: Although the median age at diagnosis of acute myeloid leukemia (AML) is 68 years, patients (PTs) aged >60 years have a 5-year relative survival of only 10–20%. Therefore, lower-intensity therapy (LIT) is often administered based on chronological age and performance status.2 However, European LeukemiaNet (ELN) 2022 risk stratification is a better predictor of clinical outcomes and patient-reported outcomes (PROs) provide complementary information regarding treatment (TX) tolerability. Longitudinal electronic PRO (ePRO) data may identify PTs at risk for TX-related toxicity and inform TX intensity decisions. We evaluated longitudinal symptom (SX) burden by ELN risk and TX intensity in PTs with AML receiving induction therapy.
Methods: PTs starting AML TX were enrolled into an ePRO system from 9/2020 to 9/2025. Baseline surveys included demographic data, geriatric assessment (GA), SX bother (GP5), physical function (PROMIS 4A) and SXs derived from PRO-CTCAE. Weekly SX surveys and TX data were collected. PTs aged ≤75 years were stratified by ELN risk (adverse [AR], intermediate [IR], favorable [FR]) and induction TX intensity: intensive therapy (IT; idarubicin or daunorubicin plus cytarabine) or lower-intensity therapy (LIT; azacitidine or decitabine plus venetoclax). SX prevalence at baseline, 6 (W6), and 12 weeks (W12) was compared using Fisher's exact test. PROMIS T-scores were using a linear mixed-effects model with time as a fixed effect and PT as a random effect. SX burden, the number of moderate/severe SX reports over time, was analyzed using a linear mixed-effects model accounting for repeated observations within PTs.
Results:
There were 128 PTs <= 75 years, median age 65 (range=24-75), 52% (n=66) male, and 79% (n=101) white. GA classified 15% as frail, 58% as intermediate fit, and 25% as fit, with no difference in TX intensity by GA category. ELN risk was adverse in 50 PTs (39%), intermediate in 45 (35%), and favorable in 33 (26%). Overall, 71 PTs (55%) received IT and 57 (45%) LIT. AR disease PTs were more likely to receive LIT than IT (56% vs. 44%, p=0.04), whereas most IR (64%) and FR (61%) PTs received IT. Baseline mean PROMIS T-score was 37.7 (population norm=50), indicating impaired physical health. At baseline, 55% PTs reported high TX bother, with similar proportions in the IT and LIT groups (55% each). Overall, 120 PTs (96%) completed SX surveys, reporting 3,717 SXs, averaging 31 SX/PT. Fatigue (15%) was the most common and most bothersome SX, followed by pain (10%), nausea (9%), decreased appetite (8%), anxiety (8%), neuropathy 7%), shortness of breath (7%), and diarrhea (6%). AR PTs reported 1,159 SXs (mean, 24/PT), IR PTs reported 1,584 (mean, 38/PT), and FR PTs reported 974 (mean, 33/PT). At baseline, the IR PTs receiving IT had a trend toward greater diarrhea (p=0.07) and neuropathy (p=0.08) compared with those receiving LIT. By W6, AR PTs receiving IT reported greater diarrhea (p=0.01) and shortness of breath (p=0.01), and more vomiting (p=0.04) and a trend toward more nausea (p=0.08), compared with AR PTs receiving LIT. No differences in SX burden by TX intensity were observed among FR PTs. By W12, SX burden was comparable between IT and LIT across all ELN risk groups, indicating early differences in TX-related SXs were transient. PROMIS T-scores did not differ from baseline at W6 or W12 in the overall cohort or among PTs receiving IT. In the LIT group, there was a trend toward improved physical health at W6 (p=0.053), although this was not sustained at W12 (p=0.643). Overall SX burden changed significantly over time (p=0.008). Among PTs receiving LIT, SX burden was lower at W6 compared with W1 (p=0.002), while the reduction at W12 did not reach significance (p=0.059). There was no difference in SX burden at W1 by TX intensity, and the time-by-TX interaction was not significant (p=0.596).
Conclusion: Longitudinal ePRO monitoring showed similar SX trajectories among PTs receiving IT and LIT induction therapy across ELN risk groups. PTs with AR AML receiving IT experienced a transient increase in SX burden at W6 that was resolved by WK12. These findings suggest integrating longitudinal PROs with ELN risk stratification may identify PTs at increased risk for TX-related toxicity, support individualized TX intensity decisions, and guide proactive SX management during AML induction therapy.
DISCLOSURES
Kayla Stewart, MS: No relevant conflicts of interest to declare.